iSpecimen Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- iSpecimen Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $4.41M.
- iSpecimen Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $3.15K, a 72.58% increase year-over-year.
- iSpecimen Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $4.41M.
- iSpecimen Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $70.89K, a 9.86% decline from fiscal 2022.
- iSpecimen Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $78.64K, a 34.09% increase from fiscal 2021.
- iSpecimen Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $58.65K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $4.41M 10-K · filed 2026-04-01 | |
| 2025-09-30 | $4.41M 10-Q · filed 2025-11-17 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $70.89K 10-K · filed 2025-04-14 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $71.14K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.15K 10-Q · filed 2024-11-07 | $72.43K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $67.74K 10-Q · filed 2024-11-07 | $71.10K derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | $254.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $78.64K 10-K · filed 2024-03-13 |
| 2022-09-30 | $1.28K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $1.83K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $75.28K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $58.65K 10-K/A · filed 2023-03-30 | |
| 2021-09-30 | $4.76K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $39.63K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |